Journal of Cancer Research and Treatment
ISSN (Print): 2374-1996 ISSN (Online): 2374-2003 Website: Editor-in-chief: Jean Rommelaere
Open Access
Journal Browser
Journal of Cancer Research and Treatment. 2015, 3(2), 28-33
DOI: 10.12691/jcrt-3-2-3
Open AccessReview Article

Breast Cancer: Insights into Risk Factors, Pathogenesis, Diagnosis and Management

Ahmed M. Kabel1, 2, and Fahad H. Baali1

1Department of Clinical Pharmacy, College of Pharmacy, Taif University, Taif, Saudi Arabia

2Department of Pharmacology, Faculty of Medicine, Tanta University, Tanta, Egypt

Pub. Date: September 13, 2015

Cite this paper:
Ahmed M. Kabel and Fahad H. Baali. Breast Cancer: Insights into Risk Factors, Pathogenesis, Diagnosis and Management. Journal of Cancer Research and Treatment. 2015; 3(2):28-33. doi: 10.12691/jcrt-3-2-3


Breast cancer is the most common invasive cancer in females worldwide. It usually presents with a lump in the breast with or without other manifestations. Diagnosis of breast cancer depends on physical examination, mammographic findings and biopsy results. Treatment of breast cancer depends on the stage of the disease. Lines of treatment include mainly surgical removal of the tumor followed by radiotherapy or chemotherapy. Other lines including immunotherapy, thermochemotherapy and alternative medicine may represent a hope for breast cancer patients.

breast cancer pathogenesis diagnosis management

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  Nelson, H.D., Smith, M.E., Griffin, J.C., Fu R., 2013. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force. Annals of Internal Medicine 158: 604-14.
[2]  Brody JG, Rudel RA, Michels KB, Moysich KB, Bernstein L, Attfield KR, et al., 2007. Environmental pollutants, diet, physical activity, body size, and breast cancer: where do we stand in research to identify opportunities for prevention?. Cancer 109: 2627-34.
[3]  Gøtzsche PC, Jørgensen KJ, 2013. Screening for breast cancer with mammography. The Cochrane database of systematic reviews 6: CD001877.
[4]  Peng J, Sengupta S, Jordan VC, 2009. Potential of Selective Estrogen Receptor Modulators as Treatments and Preventives of Breast Cancer. Anti-Cancer Agents in Medicinal Chemistry 9: 481-99.
[5]  Reeder JG, Vogel VG, 2008. Breast cancer prevention. Cancer treatment and research 141: 149-64.
[6]  Johnson KC, Miller AB, Collishaw NE, Palmer JR, Hammond SK, Salmon AG, et al., 2011. Active smoking and secondhand smoke increase breast cancer risk: the report of the Canadian Expert Panel on Tobacco Smoke and Breast Cancer Risk (2009).Tobacco control 20 (1): e2.
[7]  Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT, 2012. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. The Lancet 380 (9838): 219-29.
[8]  Biswas A, Oh PI, Faulkner GE, Bajaj RR, Silver MA, Mitchell MS, et al., 2015. Sedentary Time and Its Association With Risk for Disease Incidence, Mortality, and Hospitalization in Adults: A Systematic Review and Meta-analysis. Annals of Internal Medicine 162 (2): 123-32.
[9]  Gaffield ME, Culwell KR, Ravi A, 2009. Oral contraceptives and family history of breast cancer. Contraception 80 (4): 372-80.
[10]  Blackburn GL, Wang KA, 2007. Dietary fat reduction and breast cancer outcome: results from the Women's Intervention Nutrition Study (WINS). The American journal of clinical nutrition 86 (3): s878-81.
[11]  Kaiser J, 2013. Cancer. Cholesterol forges link between obesity and breast cancer. Science 342 (6162): 1028.
[12]  Aceves C, Anguiano B, Delgado G, 2005. Is iodine a gatekeeper of the integrity of the mammary gland?. Journal of Mammary Gland Biology and Neoplasia 10 (2): 189-96.
[13]  Gage M, Wattendorf D, Henry LR, 2012. Translational advances regarding hereditary breast cancer syndromes. J surgoncol 105 (5): 444-51.
[14]  Anothaisintawee T, Wiratkapun C, Lerdsitthichai P, Kasamesup V,Wongwaisayawan S, Srinakarin J, et al., 2013. Risk factors of breast cancer: a systematic review and meta-analysis. Asian Pacific Journal of Public Health 25 (5): 368-87.
[15]  Martin LJ, Melnichouk O, Guo H, Chiarelli AM, Hislop TG, Yaffe MJ, et al., 2010. Family history, mammographic density, and risk of breast cancer. Cancer Epidemiol Biomarkers Prev; 19(2):456-63.
[16]  Tazzite A, Jouhadi H, Saiss K, Benider A, Nadifi S, 2013. Relationship Between Family History of Breast Cancer and Clinicopathological Features in Moroccan Patients. Ethiopian Journal of Health Sciences; 23(2):150-157.
[17]  Verkooijen HM, Chappuis PO, Rapiti E, et al., 2006. Impact of familial risk factors on management and survival of early-onset breast cancer: a population-based study. Br J Cancer; 94: 231-8.
[18]  Cavalieri E, Chakravarti D, Guttenplan J, Hart E, Ingle J, Jankowiak R, et al., 2006. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. BiochimBiophysActa 1766 (1): 63-78.
[19]  Jardé T, Perrier S, Vasson MP, Caldefie-Chézet F, 2011. Molecular mechanisms of leptin and adiponectin in breast cancer. Eur J Cancer 47 (1): 33-43.
[20]  Begg CB, Haile RW, Borg A, Malone KE, Concannon P, Thomas DC, et al., 2008. Variation of breast cancer risk among BRCA1/2 carriers. JAMA 299 (2): 194-201.
[21]  Kouros-Mehr H, Kim JW, Bechis SK, Werb Z, 2008. GATA-3 and the regulation of the mammary luminal cell fate . Current opinion in cell biology 20 (2): 164-70.
[22]  Watson M, 2008. Assessment of suspected cancer. InnoAiT 1 (2): 94-107.
[23]  Zhang Y, Lv F, Yang Y, Qian X, Lang R, Fan Y, et al., 2015. Clinicopathological Features and Prognosis of Metaplastic Breast Carcinoma: Experience of a Major Chinese Cancer Center. PLoS One 10: e0131409.
[24]  Lacroix M, 2006. Significance, detection and markers of disseminated breast cancer cells. Endocrine-related Cancer (Bioscientifica) 13 (4): 1033-67.
[25]  Saslow D, Hannan J, Osuch J, Alciati MH, Baines C, Barton M, et al., 2004. Clinical breast examination: practical recommendations for optimizing performance and reporting. CA: a cancer journal for clinicians 54 (6): 327-344.
[26]  Yu YH, Liang C, Yuan XZ, 2010. Diagnostic value of vacuum-assisted breast biopsy for breast carcinoma: a meta-analysis and systematic review. Breast cancer research and treatment 120 (2): 469-79.
[27]  Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, et al., 2009. Breast cancer: Clinical practice guidelines in oncology. JNCCN 7 (2): 122-192.
[28]  Sotiriou C, Pusztai L, 2009. Gene-expression signatures in breast cancer. N Engl J Med 360 (8): 790-800.
[29]  Santana-Davila R, Perez EA, 2010. Treatment options for patients with triple-negative breast cancer. Journal of Hematology & Oncology 3: 42.
[30]  Zheng JS, Hu XJ, Zhao YM, Yang J, Li D, 2013. Intake of fish and marine n-3 polyunsaturated fatty acids and risk of breast cancer: meta-analysis of data from 21 independent prospective cohort studies. BMJ 346: f3706.
[31]  Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, et al., 2013. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 381(9880): 1827-34.
[32]  Saini KS, Taylor C, Ramirez AJ, Palmieri C, Gunnarsson U, Schmoll HJ, et al., 2011. Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries. Annals of Oncology 23 (4): 853-9.
[33]  Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al., 2011. Axillary Dissection vs No Axillary Dissection in Women with Invasive Breast Cancer and Sentinel Node Metastasis: A Randomized Clinical Trial. JAMA 305 (6): 569-575.
[34]  Nelson JC, Beitsch PD, Vicini FA, Quiet CA, Garcia D, Snider HC,et al., 2009. Four-year clinical update from the American Society of Breast Surgeons MammoSite brachytherapy trial. The American Journal of Surgery 198 (1): 83-91.
[35]  Yashar CM, Blair S, Wallace A, Scanderbeg D, 2009. Initial clinical experience with the Strut-Adjusted Volume Implant brachytherapy applicator for accelerated partial breast irradiation. Brachytherapy 8 (4): 367-72.
[36]  Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V. Bajamonde A, et al., 2001. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. New England Journal of Medicine 344 (11): 783-792.
[37]  Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al., 2006. Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer". New England Journal of Medicine 354 (8): 809-820.
[38]  Hamid O,Sznol M,Pavlick AC,Kluger HM, Kim KB, Boasberg PD,et al., 2010. Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an antibody-drug conjugate (ADC), in patients with advanced melanoma. Journal of Clinical Oncology (Meeting Abstracts) 28(15_suppl): 8525.
[39]  Thompson LU, Chen JM, Li T, Strasser-Weippl K, Goss PE, 2005. Dietary Flaxseed Alters Tumor Biological Markers in Postmenopausal Breast Cancer.Clinical Cancer Research 11 (10): 3828-3835.
[40]  Wang L, Chen J, Thompson LU, 2005. The inhibitory effect of flaxseed on the growth and metastasisof estrogen receptor negative human breast cancer xenograftsis attributed to both its lignan and oil components. International Journal of Cancer 116 (5): 793-798.
[41]  Digianni LM, Garber JE, Winer EP, 2002. Complementary and alternative medicine use among women with breast cancer. J ClinOncol 20: 34S-38S.
[42]  Hobohm U, 2009. Healing Heat: Harnessing Infection to Fight Cancer. American Scientist 97 (1): 34.
[43]  Jaganti V, Das S, Sampath TS, 2011. A review on cancer vaccines. International Journal of Pharma and Bio Sciences 2011; 2(3): 86-97.
[44]  Kim W, Lee WB, Lee JW, Min BI, Baek SK, Lee HS, et al., 2015. Traditional herbal medicine as adjunctive therapy for breast cancer: A systematic review. Complement Ther Med; 23(4):626-32.
[45]  Ma C, Li LX, Zhang Y, Xiang C, Ma T, Ma ZQ, et al., 2015. Protective and sensitive effects of melatonin combined with adriamycin on ER+ (estrogen receptor)breast cancer. Eur J Gynaecol Oncol; 36(2):197-202.
[46]  Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, et al., 2009. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27 (34): 5700-6.
[47]  Elston CW, Ellis IO, 1991. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19 (5): 403-10.
[48]  Robb C, Haley WE, Balducci L, Extermann M, Perkins EA, Small BJ, et al., 2007. Impact of breast cancer survivorship on quality of life in older women. Critical Reviews in Oncology/hematology 62 (1): 84-91.
[49]  Azim HA, Santoro L, Russell-Edu W, Pentheroudakis G, Pavlidis N, Peccatori FA, 2012. Prognosis of pregnancy-associated breast cancer: a meta-analysis of 30 studies. Cancer treatment reviews 38 (7): 834-42.